PhotoCure ASA has completed the first clinical study of photodynamic therapy (PDT) with Metvix® in the treatment of acne.
The study included 30 patients at 3 Nordic sites and was designed to compare the efficacy of Metvix PDT to placebo in patients with moderate to severe acne. The study results show that Metvix PDT gave a significantly greater reduction in the number of inflammatory acne lesions 12 weeks after treatment.
Kjetil Hestdal, President and CEO of PhotoCure, says: “We are pleased that the current study confirms our intitial observations of the possible benefits of using PhotoCures patented PDT technology in this patient group. Based on these results, we will now discuss future development strategies for this indication with Galderma.”
Acne is a common skin problem that has been reported to effect up to 85% of all adolescents. Of those who seek medical advice, about 50% have moderate and 20% have severe acne. Current therapies for these patients include oral antibiotics and isotretinoin, both products that may have significant adverse effects. There is thus a clear medical need for a safe and efficacious topical treatment for acne patients.
PhotoCure ASA is a Norwegian pharmaceutical company founded in 1993 and listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting key dermatology and oncology markets.
PhotoCure has two products with sales and marketing approvals: Metvix®, which is a product developed for the treatment of skin cancer (basal cell carcinoma) and pre-cancerous skin lesions (actinic keratosis), and Hexvix®, which is developed for the detection of bladder cancer. Both products are based on the same photodynamic technology, combining the drug known as a photosensitiser with a light source that activates the photosensitiser. PhotoCure is currently testing both products for new indications and aims to develop a pipeline of follow-on products and technologies.